| Previous close | 42.90 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | 15.485M |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.37 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
EQS-News: Biotest AG / Key word(s): SustainabilityBiotest AG: Biotest presents gigantic artwork to visualize its sustainability initiatives 01.06.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest presents gigantic artwork to visualize its sustainability initiatives International Eco-Art artist creates large-scale mural to visualize company's sustainability efforts Special paint with sophisticated technology creates air-purifying eff
EQS-News: Biotest AG / Key word(s): Personnel/AGM/EGMBiotest AG: Annual General Meeting of Biotest AG elects Raimon Grifols Roura to the Supervisory Board 09.05.2023 / 16:30 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE Annual General Meeting of Biotest AG elects Raimon Grifols Roura to the Supervisory Board Broad majority on all agenda items according to the proposals of the administration Q1 report published Dreieich, 9 May 2023. 96 shareholders a
EQS-News: Biotest AG / Key word(s): Regulatory ApprovalBiotest AG: Biotest’s Hyperimmunoglobulin Cytotect® CP receives five additional Marketing Authorisations in Europe 04.05.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest’s Hyperimmunoglobulin Cytotect® CP receives five additional Marketing Authorisations in Europe Approval of Biotest’s CMV-hyperimmunoglobulin in now 28 markets will secure future revenue growth Biotest’s CMV-hyper
Biotest AG / Key word(s): AllianceBiotest AG: Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised28-Apr-2023 / 10:04 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Ad hoc NOTICE Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR) Biotest and Grifols further str
EQS-News: Biotest AG / Key word(s): MiscellaneousBiotest AG: Biotest AG opens 12th plasma collection centre in Hungary 25.04.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest AG opens 12th plasma collection centre in Hungary 36 plasma collection stations in Europe to secure the plasma supply in the long termDreieich, 25 April 2023. Biotest has officially opened the 12th plasma collection centre in Hungary in Budapest, after previous
EQS-News: Biotest AG / Key word(s): MiscellaneousBiotest AG: Biotest AG opens 10th plasma collection centre in Germany 20.04.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest AG opens 10th plasma collection centre in Germany 35 plasma collection centres in Europe to secure long term plasma supply Dreieich, 20 April 2023. Biotest has officially opened the 10th plasma collection centre in Germany in Münster in Westphalia.In future, pl
EQS-News: Biotest AG / Key word(s): StudyBiotest AG: Biotest achieves important milestone in phase III trial in acquired fibrinogen deficiency 30.03.2023 / 08:48 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest achieves important milestone in phase III trial in acquired fibrinogen deficiency Successful interim analysis performed with 80% of evaluable patients Originally planned number of patients confirmed Completion of trial expected in 2023 A
EQS-News: Biotest AG / Key word(s): Annual ResultsBiotest AG: Biotest core business profitable at Euro 60.7 million 23.03.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest core business profitable at Euro 60.7 million First product from Biotest Next Level facility: approval and market launch of Yimmugo in November 2022 34 own plasma collection centres in Europe Biotest invites to the Annual General Meeting on 9 May 2023 Dreieich, 23
EQS-News: Biotest AG / Key word(s): MiscellaneousBiotest AG: Biotest donates human albumin for earthquake victims in Turkey 14.03.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest donates human albumin for earthquake victims in Turkey Almost 2,000 severely affected victims can be supplied with human albumin Close interaction with Turkish Red Crescent (Kizilay) and the Turkish-German Health Foundation e.V. (Türk Alman Saglik Vakfi)Dr
EQS-News: Biotest AG / Key word(s): PersonnelBiotest AG: Biotest Supervisory Board appoints new Management Board member 10.02.2023 / 11:46 CET/CESTThe issuer is solely responsible for the content of this announcement.PRESS RELEASE Biotest Supervisory Board appoints new Management Board member Ainhoa Mendizabal will assume the position of Chief Financial Officer (CFO) on the Management Board on 15 FebruaryDreieich, 10 February 2023. The Supervisory Board of Biotest AG has appointed Ms Ainhoa Mend
Biotest AG / Key word(s): Preliminary ResultsBiotest AG: Biotest significantly exceeds EBIT guidance 202209-Feb-2023 / 14:19 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Ad hoc NOTICE Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR) Biotest significantly exceeds EBIT guidance 2022 Dreieich, 09 February
EQS-News: Biotest AG / Key word(s): StudyBiotest AG: First patient treated with Cytotect® CP Biotest in study after heart and lung transplantation 24.01.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE First patient treated with Cytotect® CP Biotest in study after heart and lung transplantation High medical need due to severe cytomegalovirus (CMV) infections and resulting mortality after organ transplantation Study will provide data to opt
EQS-News: Biotest AG / Key word(s): MiscellaneousBiotest AG: Biotest receives 'Innovation Champion of Sustainability' award 19.01.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest receives "Innovation Champion of Sustainability" award Biotest achieves very good 5th place in sustainability analysis by F.A.Z.-Institute With its GoFuture sustainability initiative, Biotest aims to grow in line with social and ecological requirements. Dr
EQS-News: Biotest AG / Key word(s): StudyBiotest AG: Biotest treats first COVID-19 patients with trimodulin in TRICOVID phase III trial 10.01.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement.PRESS RELEASE Biotest treats first COVID-19 patients with trimodulin in TRICOVID phase III trial Trimodulin is a worldwide unique, innovative human plasma protein preparation in advanced development Significant reduction in clinical deterioration and mortality expect
EQS-News: Biotest AG / Key word(s): StudyBiotest AG: First patient enrolled in phase II clinical trial for treatment of chronic hepatitis B with hyperimmunoglobulins 08.12.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE First patient enrolled in phase II clinical trial for treatment of chronic hepatitis B with hyperimmunoglobulins High medical need for 300 million patients with chronic hepatitis B worldwide Further development of hepatiti
EQS-News: Biotest AG / Key word(s): 9 Month figuresBiotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022 14.11.2022 / 09:35 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest reports sales of € 361 million in the first nine months of 2022 Robust Q1-Q3 2022 sales in a challenging macroeconomic context Biotest receives marketing authorization for new intravenous immunoglobulin Yimmugo® (IgG Next Generation) Opening
EQS-News: Biotest AG / Key word(s): Regulatory ApprovalBiotest AG: Biotest receives approval for new intravenous immunoglobulin Yimmugo® (IgG Next Generation) 14.11.2022 / 09:30 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest receives approval for new intravenous immunoglobulin Yimmugo® (IgG Next Generation) New innovative immunoglobulin expands Biotest's product portfolio First sales expected before end of this year in Germany as first countr
EQS-News: Biotest AG / Key word(s): MiscellaneousBiotest AG: Biotest AG opens 14th plasma collection centre in the Czech Republic 13.10.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest AG opens 14th plasma collection centre in the Czech Republic 34 plasma collection stations in Europe to secure the plasma supply in the long termDreieich, 13 October 2022. Biotest has received the operating licence for the 14th plasmapheresis centre
EQS-News: Biotest AG / Key word(s): MiscellaneousBiotest AG: Biotest AG opens 13th plasma collection centre in the Czech Republic 26.09.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest AG opens 13th plasma collection centre in the Czech Republic 33 plasma collection stations in Europe to secure the plasma supply in the long termDreieich, 26 September 2022. Biotest has received the operating licence for the 13th Cara Plasma plasmaph
DGAP-News: Biotest AG / Key word(s): MiscellaneousBiotest AG: Biotest AG opens 12th plasma collection centre in the Czech Republic 06.09.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest AG opens 12th plasma collection centre in the Czech Republic 32 plasma collection stations in Europe to secure the plasma supply in the long termDreieich, 06 September 2022. Biotest has received the operating licence for the 12th Cara Plasma plasmap
DGAP-News: Biotest AG / Key word(s): Half Year ResultsBiotest AG: Biotest achieves an improved adjusted EBIT by 9.8% of EUR 32.4 million in the first half of 2022 11.08.2022 / 07:00 The issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest achieves an improved adjusted EBIT by 9.8% of € 32.4 million in the first half of 2022 Biotest almost reaches previous year's turnover of € 253 million in a difficult environment Opening of four plasma collection centres in t
DGAP-News: Biotest AG / Key word(s): Half Year ResultsBiotest AG: Biotest increases EBITDA in first half-year by 52% to 8.8 million EUR 28.07.2022 / 08:30 The issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest increases EBITDA in first half-year by 52% to 8.8 million EUR Biotest almost achieves previous year's sales in difficult environment Opening of 4 plasma collection centres in the first half of the year More plasma centres planned in 2022 Dreieich, 28 J
DGAP-News: Biotest AG / Key word(s): MiscellaneousBiotest AG: Biotest grants Renate & Hans Schleussner Research Award for the first time 25.07.2022 / 10:31 The issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest grants Renate & Hans Schleussner Research Award for the first time Renate & Hans Schleussner Award endowed with € 50,000 Research project awarded for laboratory studies on the mode of action of cytomegalovirus (CMV) hyperimmunoglobulins in pregnancy t
DGAP-News: Biotest AG / Key word(s): Research UpdateBiotest AG: Biotest achieves important milestone in Phase III study in acquired fibrinogen deficiency 10.06.2022 / 07:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest achieves important milestone in Phase III study in acquired fibrinogen deficiency Successful interim analysis after 120 patients Number of patients originally planned for study confirmed Results are the basis for approval in patients wi
DGAP-News: Biotest AG / Key word(s): MiscellaneousBiotest AG: Biotest AG opens 11th plasma collection centre in Czech Republic 09.06.2022 / 07:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest AG opens 11th plasma collection centre in Czech Republic 31 plasma collection centres in Europe to ensure long-term plasma supplyDreieich, 9 June 2022. Biotest has received the operating license for its eleventh plasma collection centre in Czech Republic from the